Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avient Corporation (AVNT) vs Medpace Holdings Inc (MEDP) Price & Performance

Avient CorporationTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Avient Corporation vs Medpace Holdings Inc — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 4.1× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

AVNTMEDP
Market Cap
$4.17B$16.90B
Sector
TechnologyTechnology
52-Week High
$45.69$620.59
52-Week Low
$27.48$393.42
Enterprise Value
$5.62B$16.52B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avient Corporation

Avient (AVNT) trades at $45.1, down 1.2% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue remains stable at $3.3 billion, with a net income margin improving to 5.1% in 2026. Analysts maintain a Buy consensus with a $49 price target, reflecting optimism about continued growth and dividend stability.

The stock offers upside potential from earnings momentum and a solid dividend yield, but faces risks from macroeconomic pressures on materials demand and high RSI levels suggesting overbought conditions. Institutional sentiment is positive, with no Sell ratings, though investors should monitor debt levels and competitive dynamics in the chemical sector for sustained performance.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Avient Corporation

Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.

Read more on AVNT

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP